Education, Science, Technology, Innovation and Life
Open Access
Sign In

The relationship between B vitamin supplementation and pruritus incidence in adults a systematic review and meta-analysis

Download as PDF

DOI: 10.23977/medsc.2023.040807 | Downloads: 10 | Views: 278


Gangkui He 1, Xiaodong Luo 1, Kui Yuan 1


1 Dazhou Hospital of Integrated Traditional and Western Medicine, Dazhou, Sichuan, China

Corresponding Author

Gangkui He


We aim to assess the prevalence of pruritus or itching in adult patients taking Vitamin B supplementation. The method applied in this paper is a systemic search was conducted from electronic databases (PubMed/Medline, Cochrane Library, and Google Scholar) from inception to 30th October 2023. All statistical analyses were conducted in Review Manager 5.4.1. Studies meeting inclusion criteria were selected. A random-effect model was used when heterogeneity was seen to pool the studies, and the result was reported in prevalence and their corresponding 95% confidence interval (CI). Five studies (three randomized controlled trials and two observational studies) were included in our analysis. We analyzed the prevalence of vitamin B3 (niacin) and B12 (cyanocobalamin). There was a statistically significant prevalence of pruritis in participants treated with niacin (prevalence = 18% (9%, 26%); p < 0.0001; I2 = 98%) and cyanocobalamin (prevalence = 46% (32%, 60%); p < 0.00001; I2 = Not applicable). Hence, the overall prevalence was (prevalence = 22% (14%, 31%); p < 0.00001; I2 = 98%).Our study showed that patients taking vitamin B3 supplementation and B12 supplementation had 18% and 46%, respectively, prevalence of pruritus. Overall, there was a 22% prevalence.


Vitamin B, Pruritus, Prevalence


Gangkui He, Xiaodong Luo, Kui Yuan, The relationship between B vitamin supplementation and pruritus incidence in adults a systematic review and meta-analysis. MEDS Clinical Medicine (2023) Vol. 4: 41-48. DOI:


[1] Carlson L. A. (2005). Nicotinic acid: the broad-spectrum lipid drug. A 50th-anniversary review. Journal of internal medicine, 258(2), 94–114.
[2] M. Keenan, J. (2019). The Role of Niacin in the Management of Dyslipidemia. IntechOpen.doi: 10.5772/ intechopen. 81725
[3] Boden, W. E., Sidhu, M. S., & Toth, P. P. (2014). The therapeutic role of niacin in dyslipidemia management. Journal of cardiovascular pharmacology and therapeutics, 19(2), 141–158.
[4] Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., Pessah-Pollack, R., Wyne, K., Smith, D., Brinton, E. A., Fazio, S., & Davidson, M. (2017). American Association of Clinical Endocrinologists and American College Of Endocrinology Guidelines for Management Of Dyslipidemia And Prevention Of Cardiovascular Disease. Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 23(Suppl 2), 1–87.
[5] Kamanna, V. S., & Kashyap, M. L. (2008). Mechanism of action of niacin. The American journal of cardiology, 101(8A), 20B–26B.
[6] Niacin. (2023, August 10). Mayo Clinic.
[7] Vanhorn, J., Altenburg, J. D., Harvey, K. A., Xu, Z., Kovacs, R. J., & Siddiqui, R. A. (2012). Attenuation of niacin-induced prostaglandin D(2) generation by omega-3 fatty acids in THP-1 macrophages and Langerhans dendritic cells. Journal of inflammation research, 5, 37–50.
[8] Davidson M. H. (2008). Niacin use and cutaneous flushing: mechanisms and strategies for prevention. The American journal of cardiology, 101(8A), 14B–19B.
[9] Whelan, A. M., Price, S. O., Fowler, S. F., & Hainer, B. L. (1992). The effect of aspirin on niacin-induced cutaneous reactions. The Journal of family practice, 34(2), 165–168.
[10] Atopic dermatitis: MedlinePlus medical encyclopedia. (n.d.). MedlinePlus - Health Information from the National Library of Medicine.
[11] Hanifin J. M. (1991). Atopic dermatitis: new therapeutic considerations. Journal of the American Academy of Dermatology, 24(6 Pt 2), 1097–1101.
[12] Hewett, L. (2021, July 13). Understanding inflammation's role in atopic dermatitis. National Eczema Association.
[13] Jung, S. H., Cho, Y. S., Jun, S. S., Koo, J. S., Cheon, H. G., & Shin, B. C. (2011). Topical application of liposomal cobalamin hydrogel for atopic dermatitis therapy. Die Pharmazie, 66(6), 430–435.
[14] Chesini Ms, D., & Caminati Md, M. (2022). Vitamin B12 and Atopic Dermatitis: Any Therapeutic Relevance For Oral Supplementation?. Journal of dietary supplements, 19(2), 238–242. 1080/19390211. 2020. 1860180
[15] Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015 Jun 2; 162(11):777-784. doi: 10.7326/M14-2385. PMID: 26030634.
[16] Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019; 10(10):ED000142. doi:10.1002/14651858.ED000142
[17] Birjmohun, R. S., Kastelein, J. J., Poldermans, D., Stroes, E. S., Hostalek, U., & Assmann, G. (2007). Safety and tolerability of prolonged-release nicotinic acid in statin-treated patients. Current medical research and opinion, 23(7), 1707–1713.
[18] Kashyap, M. L., McGovern, M. E., Berra, K., Guyton, J. R., Kwiterovich, P. O., Harper, W. L., Toth, P. D., Favrot, L. K., Kerzner, B., Nash, S. D., Bays, H. E., & Simmons, P. D. (2002). Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. The American journal of cardiology, 89(6), 672–678.
[19] Norquist, J. M., Watson, D. J., Yu, Q., Paolini, J. F., McQuarrie, K., & Santanello, N. C. (2007). Validation of a questionnaire to assess niacin-induced cutaneous flushing. Current medical research and opinion, 23(7), 1549–1560.
[20] Mills, E., Prousky, J., Raskin, G., Gagnier, J., Rachlis, B., Montori, V. M., & Juurlink, D. (2003). The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]. BMC clinical pharmacology, 3, 4.
[21] Stücker, M., Pieck, C., Stoerb, C., Niedner, R., Hartung, J., & Altmeyer, P. (2004). Topical vitamin B12--a new therapeutic approach in atopic dermatitis-evaluation of efficacy and tolerability in a randomized placebo-controlled multicentre clinical trial. The British journal of dermatology, 150(5), 977–983.
[22] Guyton, J. R., & Bays, H. E. (2007). Safety considerations with niacin therapy. The American journal of cardiology, 99(6A), 22C–31C.
[23] Schandelmaier, S., Briel, M., Saccilotto, R., Olu, K. K., Arpagaus, A., Hemkens, L. G., & Nordmann, A. J. (2017). Niacin for primary and secondary prevention of cardiovascular events. The Cochrane database of systematic reviews, 6(6), CD009744.
[24] Kamanna, V. S., Ganji, S. H., & Kashyap, M. L. (2009). The mechanism and mitigation of niacin-induced flushing. International journal of clinical practice, 63(9), 1369–1377.
[25] Just a moment... (n.d.). Just a moment... cyanocobalamin - topical-cream/
[26] Chesini Ms, D., & Caminati Md, M. (2022). Vitamin B12 and Atopic Dermatitis: Any Therapeutic Relevance For Oral Supplementation? Journal of dietary supplements, 19(2), 238–242. 1080/19390211. 2020. 1860180

Downloads: 4795
Visits: 209433

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.